role of rebates in glp-1 pbm decisions Regulations on Drug Spending PBMs, Formularies, and Rebates: The

Implications for marketers: Interest in GLP-1s is highest among consumers diagnosed as overweight or obese, but weight loss isnt always what motivates people to use GLP-1s

However, the sustainability of these outcomes often depends on continued treatment, reinforcing the view of obesity as a chronic disease requiring long-term pharmacological management

04 Shipping and Tracking We ship the medication to the patient, providing tracking details via text

These therapies differ by active ingredient, delivery method, dosing frequency, and FDA-approved indication

Key findings from the research include: A significant association between GLP-1 medication use and increased risk of gastroparesis A 3.67-fold increase in the risk of developing gastroparesis among GLP-1 medication users An incidence rate of 0.53% among users of these medications These findings highlight the need for healthcare providers and patients to be aware of GLP-1 medication risks